Market News & Trends
Vyluma & Laboratoires Théa Enter Licensing Agreement for the Registration & Commercialization of NVK002 in Canada, Mexico & Select South American Countries
Vyluma, Inc. and Laboratoires Théa recently announced they have recently entered into an exclusive licensing agreement for the registration and commercialization of NVK002 in Canada,…
Olema Oncology Provides Clinical Update Reflecting Strong Progress Across OP-1250 Development Program
Olema Pharmaceuticals, Inc. recently announced clinical development progress for OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) in development…
Catalent Supports US Launch of Phathom Pharmaceuticals’ New Products Following Regulatory Approval
Catalent welcomed the recent announcement by Phathom Pharmaceuticals the US FDA has approved both VOQUEZNA TRIPLE PAK (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA…
First Patient Dosed in Second Phase 2 Add-on Ketamine Trial in Treatment-Resistant Depression
HMNC Brain Health, together with Develco Pharma, recently announced the dosing of the first patient in their second Phase 2 trial with oral prolonged-release Ketamine…
Catalent & MigVax Sign Agreement to Develop an Orally Disintegrating Freeze-Dried Tablet Vaccine Against COVID-19
Catalent and MigVax recently announced they have signed a development agreement to leverage Catalent’s proprietary Zydis Bio orally disintegrating tablet (ODT) technology for delivering the…
Apellis & Sobi Announce First Patient Dosed in Phase 3 Study of Pegcetacoplan for IC-MPGN & C3G, Rare Kidney Diseases With High Unmet Medical Need
Apellis Pharmaceuticals, Inc. and Sobi recently announced the first patient has been dosed in the Phase 3 VALIANT study investigating pegcetacoplan, a targeted C3 therapy,…
ProteoGenix, Aseem Healthcare & Trident Biopharm Solutions Announce New Antibody Cocktail Effective Against Major Variants of SARS-CoV-2
ProteoGenix, Aseem Healthcare, and Trident Biopharm Solutions recently announced the development of a new antibody cocktail effective against major variants of SARS-CoV-2. The cocktail of…
Evonik Launches New Peptide to Boost Productivity of Cell-Culture-Based Biopharmaceuticals
Evonik now offers a highly pure cystine peptide to address challenges in the formulation of cell culture media and processes used in the development and…
Assembly Biosciences Initiates Phase 1b Clinical Trial Evaluating Next-Generation Core Inhibitor
Assembly Biosciences, Inc. recently announced the initiation of a Phase 1b trial of its investigational next-generation, highly potent core inhibitor ABI-H3733 (3733). 3733 has demonstrated…
Zai Lab & Novocure Announce Phase 2 Pilot Study Evaluating Tumor Treating Fields Together With Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer
Zai Lab and Novocure recently announced the EF-31 Phase 2 pilot study, testing the safety and efficacy of Tumor Treating Fields (TTFields) together with standard-of-care…
EXCLUSIVE ONLINE CONTENT
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….